HSBC Holdings
PRQR icon

HSBC Holdings’s ProQR Therapeutics PRQR Stock Holding History

HSBC Holdings’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-500,000
Closed -$4.55M – 3134
2019
Q2 		$4.55M Hold
500,000
– – 0.01% 1180
2019
Q1 		$6.93M Hold
500,000
– – 0.01% 986
2018
Q4 		$7.89M Buy
+500,000
New +$9.18M 0.01% 932

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

HSBC Holdings's PRQR Position: Q3 2019 in Review

HSBC Holdings sold out of ProQR Therapeutics (PRQR) in Q3 2019, closing a stake of 500,000 shares — an estimated $4.55M sold.

HSBC Holdings first reported a position in PRQR in Q4 2018 and held it in 3 quarters. The position peaked at $7.89M in Q4 2018. 50 funds tracked by Wall St. Rank hold PRQR as of Q3 2019.

  • HSBC Holdings reported no remaining ProQR Therapeutics position as of Q3 2019 after selling out during the quarter.
  • HSBC Holdings sold 500,000 ProQR Therapeutics shares in Q3 2019, an estimated $4.55M.
  • HSBC Holdings first reported a position in ProQR Therapeutics in Q4 2018 and held it in 3 quarters.
  • HSBC Holdings's ProQR Therapeutics position peaked at $7.89M in Q4 2018.
  • 50 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2019.

Based on HSBC Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.